Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

This study has been terminated.
Information provided by (Responsible Party):
Oxford BioMedica Identifier:
First received: September 2, 2010
Last updated: November 26, 2012
Last verified: February 2012
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: March 2013
  Estimated Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)